Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Mantle Cell Lymphoma

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Mantle Cell Lymphoma

Expert Highlights Advances in MCL and DLBCL

Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.
Read More >>

Wang Highlights Encouraging CAR T-Cell Activity in MCL

Maintenance Rituximab After R-CHOP Shows Continued Benefit in Older Patients With MCL

FDA Approval Sought for KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma

ASH 2019: KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned

ASH 2019: Ibrutinib May Thwart PFS Decline in R/R Mantle Cell Lymphoma

View More Stories >>

View Conference Coverage

2020 SGO Winter Meeting

2020 Gastrointestinal Cancers Symposium

2019 San Antonio Breast Cancer Symposium

2019 ASH Annual Meeting

2019 International Congress of the Society for Melanoma Research

Dr. Ramakrishnan on Benefit of CAR T-Cell Therapy in MCL

$Dr. Wang on the ZUMA-2 Trial in Relapsed/Refractory MCL$

Dr. Wang on the ZUMA-2 Trial in Relapsed/Refractory MCL

Dr. Wang on Precision Medicine in MCL

Dr. Rule on the Next Steps for BTK Inhibitors in MCL

Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCL

$Dr. Goy on Preliminary Data With Ibrutinib/Venetoclax in Relapsed/Refractory MCL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Practical Advice on the Future Management of MCL

R/R MCL: Synchronizing Older and Newer Therapeutic Strategies

$Selection of a BTK Inhibitor in Relapsed/Refractory MCL$

Selection of a BTK Inhibitor in Relapsed/Refractory MCL

Mantle Cell Lymphoma: An Overview on Frontline Therapy

Highlights from ASH 2017: Mantle Cell Lymphoma

Investigational Treatment in Mantle Cell Lymphoma

Future Therapy: Bruton's TKI Containing Combinations in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

First-Generation BTK Inhibition in Mantle Cell Lymphoma

Advice for Future Management of Mantle Cell Lymphoma

Non-BTKi Agents' Role in Mantle Cell Lymphoma

MCL: Novel BTK Inhibitor Combination Strategies

$Identifying Unmet Needs in Relapsed/Refractory MCL$

Differentiating BTK Inhibitor Mechanisms of Action in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Ibrutinib in Relapsed Mantle Cell Lymphoma

Drs Danilov, Goy, Leonard, Pagel, and Schuster, discuss ibrutinib (Imbruvica) as a treatment in relapsed mantle cell lymphoma. View Now

Treatments for Relapsed Mantle Cell Lymphoma

Brad S. Kahl, MD, and Richard R. Furman, MD, explain available treatment options for relapsed mantle cell lymphoma. View Now

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approvals in Urothelial Cancer and GIST, Promising Data in Urothelial Carcinoma, and More